Literature DB >> 27337654

Progress and potential impact of RET kinase targeting in cancer.

Lois M Mulligan1.   

Abstract

Entities:  

Keywords:  RET; cabozantinib; kinase inhibitor; lung adenocarcinoma; precision oncology; thyroid carcinoma; vandetanib

Mesh：

Substances：

Year:  2016        PMID： 27337654     DOI： 10.1080/14789450.2016.1205491

Source DB:  PubMed          Journal:  Expert Rev Proteomics        ISSN： 1478-9450            Impact factor:   3.940


× No keyword cloud information.
  2 in total

1.  Drug resistance profiles of mutations in the RET kinase domain.

Authors:  Xuan Liu; Tao Shen; Blaine H M Mooers; Frank Hilberg; Jie Wu
Journal:  Br J Pharmacol       Date:  2018-07-19       Impact factor: 8.739

2.  Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.

Authors:  Ezra Y Rosen; Melissa L Johnson; Alexander Drilon; Geoffrey R Oxnard; Sarah E Clifford; Romel Somwar; Jennifer F Kherani; Jieun Son; Arrien A Bertram; Monika A Davare; Eric Gladstone; Elena V Ivanova; Dahlia N Henry; Elaine M Kelley; Mika Lin; Marina S D Milan; Binoj C Nair; Elizabeth A Olek; Jenna E Scanlon; Morana Vojnic; Kevin Ebata; Jaclyn F Hechtman; Bob T Li; Lynette M Sholl; Barry S Taylor; Marc Ladanyi; Pasi A Jänne; S Michael Rothenberg
Journal:  Clin Cancer Res       Date:  2020-10-20       Impact factor: 13.801
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.